07 Oct 2026

Norway's Ministry of Health and Care Services (Helse- og omsorgsdepartementet) has opened consultation on changes to individual access to investigational medicines for people with serious illness, short life expectancy and no established treatment options. The consultation, published on 5 October, follows an expert report delivered on 2 October.

Current rules allow the Norwegian Medical Products Agency (Direktoratet for medisinske produkter, DMP) to grant individual exemptions from marketing-authorisation requirements. Access may also be available through compassionate-use programmes, but medicines in early development present difficulties where evidence of quality, safety or effectiveness is limited.

The expert group proposes a specific regulatory provision for exemptions in these circumstances, alongside revisions to the existing exemption rule. It also recommends clearer administrative guidance, more consistent handling of applications and appeals, and measures to strengthen early-stage clinical trials.

The report identifies separate responsibilities for the treating clinician, healthcare organisation, regulator and manufacturer. A regulatory exemption alone cannot secure access where the manufacturer is unwilling or unable to supply the product. The group records minority disagreement on several central recommendations.

Consultation responses are invited until 5 January 2027. Any regulatory amendments would require further government action; the current framework continues to apply during the consultation.

Source: Norwegian Ministry of Health and Care Services
Link: Høring av rapporten – Tidlig tilgang til legemidler for alvorlig syke med kort forventet levetid (Consultation on the report – early access to medicines for seriously ill patients with a short life expectancy)
Date: 5 October 2026

Source: Norwegian Ministry of Health and Care Services
Link: Tidlig tilgang til legemidler for alvorlig syke med kort forventet levetid (Early access to medicines for seriously ill patients with a short life expectancy)
Date: 2 October 2026